Search Results - "Hounsome, L"

Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England by Hounsome, L., Eyre, T. A., Ireland, R., Hodson, A., Walewska, R., Ardeshna, K., Chaganti, S., McKay, P., Davies, A., Fox, C. P., Kalakonda, N., Fields, P. A.

“…Background We wished to examine treatment and outcome patterns in older diffuse large B-cell lymphoma (DLBCL) patients, with a focus on the effect of…”
Get full text

Epidemiological impact of a large number of false negative SARS-CoV-2 test results in South West England during September and October 2021 by Hounsome, L., Herr, D., Bryant, R., Smith, R., Loman, L., Harris, J., Youhan, U., Dzene, E., Hadjipantelis, P., Long, H., Laurence, T., Riley, S., Cumming, F.

“…During September and October 2021, a substantial number of Polymerase Chain Reaction (PCR) tests in England processed at a single laboratory were incorrectly…”
Get full text

Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study by Battisti, N.M.L., Wallington, M., Ring, A., Payne, S., Birch, R., Bomb, M., Seligmann, J., Kalsi, T., Hounsome, L., Dodwell, D., Underhill, S., Mensah, L., Morris, E., Selby, P.J., Mansi, J.

Get full text

National trends in the place of death and the impact of unscheduled admissions in patients with gynecological cancer in England by Hounsome, L, Blinman, C, Glew, S, Gornall, R, Verne, J

Get full text

Treatment and survival in non-metastatic muscle invasive bladder cancer: Analysis of a national patient cohort by John, J.B., Varughese, M., Cooper, N., Wong, K., Hounsome, L., Treece, S., McGrath, J.S., Harden, S.

Get full text

Photoelastic constants in diamond and silicon by Hounsome, L. S., Jones, R., Shaw, M. J., Briddon, P. R.

“…Ab Initio calculations, using density functional theory within the AIMPRO code, have been performed on bulk diamond and silicon in order to calculate the…”
Get full text

Trends in incidence, mortality and treatment of penile cancer before and after centralisation of penile cancer services in England (1990–2009) by Ayres, BE, Iles, M, Hounsome, L, McPhail, S, Persad, R, Verne, J, Watkin, NA

“…Objective: Penile cancer services were centralised in England in 2002. Has this had an impact on treatments for penile cancer and survival? Patients and…”
Get full text

Validation of The Hospital Episode Statistics Outpatient Dataset in England by Thorn, J.C, Turner, E, Hounsome, L, Walsh, E, Down, L, Donovan, J, Verne, J, Neal, D, Hamdy, F, Martin, R.M, Noble, S

Get full text

MP-04.11 Trends in Bladder Cancer Incidence and Mortality in England 1990-2006 by Eylert, M, Persad, R, Hounsome, L, Verne, J, Jefferies, E, Bahl, A, Mostafid, H

Get full text

POD-03.03 Increased Cardiac Admission Rates in Prostate Cancer Patients Treated with Androgen Deprivation Therapy in England by Jefferies, E, Bahl, A, Hounsome, L, Eylert, M, Verne, J, Persad, R

Get full text

The impact of socio-economic deprivation on incidence, treatment and mortality from prostate cancer in England, 1990–2010 by Eylert, MF, Bahl, A, Hounsome, L, Verne, J, Jefferies, ER, Persad, RA

“…Objective: To explore any association between socio-economic deprivation and prostate cancer diagnosis and/or treatment. Patients and methods: Data was…”
Get full text

Optical properties of vacancy related defects in diamond by Hounsome, L. S., Jones, R., Martineau, P. M., Shaw, M. J., Briddon, P. R., Öberg, S., Blumenau, A. T., Fujita, N.

“…〈110〉 vacancy chains, multi‐vacancy clusters and vacancy discs have been modeled using density functional theory within the AIMPRO and DFTB codes. While a…”
Get full text

Electron energy loss spectroscopic studies of brown diamonds by Bangert, U., Barnes, R., Hounsome, L. S., Jones, R., Blumenau, A. T., Briddon, P. R., Shaw, M. J., Öberg, S.

“…We investigate both experimentally and theoretically, low-loss electron energy losses in brown type IIa monocrystalline diamonds both before and after…”
Get full text

Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements by Eylert, MF, Hounsome, LS, Persad, RA, Bahl, A, Jefferies, ER, Verne, J, Mostafid, H

“…Objective The objective of this article is to obtain up-to-date epidemiological statistics of bladder cancer in England. Methods We collected incidence from…”
Get full text

The BAUS radical cystectomy audit 2014/2015 - an update on current practice and an analysis of the effect of centre and surgeon case volume by Khadhouri, S, Miller, C, Cresswell, J, Rowe, E, Fowler, S, Hounsome, L, McGrath, J.S

Get full text

The BAUS radical prostatectomy audit 2014/2015 – an update on current practice and outcomes by centre and surgeon case volume by Khadhouri, S, Miller, C, McNeill, A, Hounsome, L, Fowler, S, McGrath, J

Get full text

Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE by Mintz, H.P., Amos, C., Brannan, R., Brawley, C., Calvert, J., Gannon, M.R., Hounsome, L., Ingleby, F.C., McPhail, S., Parmar, M.K.B., Parsons, H.M., Patel, P., Rauchenberger, M., Sydes, M.R., Wu, H., James, N.D.

Get full text

862PRetrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE by Mintz, H P, Amos, C, Brannan, R, Brawley, C, Calvert, J, Gannon, M R, Hounsome, L, Ingleby, F C, McPhail, S, Parmar, M K B, Parsons, H M, Patel, P, Rauchenberger, M, Sydes, M R, Wu, H, James, N D

“…Abstract Background Docetaxel (Doc) was initially licenced for CRPC (TAX327) but more recently trials showed Doc at HSPC diagnosis improved survival, shifting…”
Get full text

862P - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE by Mintz, H.P., Amos, C., Brannan, R., Brawley, C., Calvert, J., Gannon, M.R., Hounsome, L., Ingleby, F.C., McPhail, S., Parmar, M.K.B., Parsons, H.M., Patel, P., Rauchenberger, M., Sydes, M.R., Wu, H., James, N.D.

“…Docetaxel (Doc) was initially licenced for CRPC (TAX327) but more recently trials showed Doc at HSPC diagnosis improved survival, shifting patterns of use…”
Get full text

DECISION REGRET IN MEN TREATED FOR LOCALISED PROSTATE CANCER: RESULTS FROM THE LIFE AFTER PROSTATE CANCER DIAGNOSIS STUDY by Downing, A, Wright, P, Watson, E, Wagland, R, Hounsome, L, Butcher, H, Gavin, A, Glaser, AW

Get full text